Michael S Hofman

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/1735518/publications.pdf

Version: 2024-02-01

256	13,862	30070 54	24258 110
papers	citations	h-index	g-index

258	258	258	9686
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Tumor Sink Effect in ⁶⁸Ga-PSMA-11 PET: Myth or Reality?. Journal of Nuclear Medicine, 2022, 63, 226-232.	5.0	42
2	Appropriate Use Criteria for Prostate-Specific Membrane Antigen PET Imaging. Journal of Nuclear Medicine, 2022, 63, 59-68.	5.0	61
3	Imaging of Neuroendocrine Neoplasms: Monitoring Treatment Responseâ€"AJR Expert Panel Narrative Review. American Journal of Roentgenology, 2022, 218, 767-780.	2.2	15
4	Chimeric Antigen Receptor T-Cell Therapy in Metastatic Castrate-Resistant Prostate Cancer. Cancers, 2022, 14, 503.	3.7	21
5	PET imaging of prostate cancer. , 2022, , .		0
6	What Experts Think About Prostate Cancer Management During the COVID-19 Pandemic: Report from the Advanced Prostate Cancer Consensus Conference 2021. European Urology, 2022, 82, 6-11.	1.9	4
7	The PRIMARY Score: Using intra-prostatic PSMA PET/CT patterns to optimise prostate cancer diagnosis.. Journal of Nuclear Medicine, 2022, , jnumed.121.263448.	5.0	20
8	[68Ga]Ga-PSMA Versus [18F]PSMA Positron Emission Tomography/Computed Tomography in the Staging of Primary and Recurrent Prostate Cancer. A Systematic Review of the Literature. European Urology Oncology, 2022, 5, 273-282.	5.4	37
9	Radiation Dosimetry in 177Lu-PSMA-617 Therapy. Seminars in Nuclear Medicine, 2022, 52, 243-254.	4.6	16
10	High prostateâ€specific membrane antigen (<scp>PSMA) positron emission tomography (PET)</scp> maximum standardized uptake value in men <scp>with PIâ€RADS</scp> score 4 or 5 confers a high probability of significant prostate cancer. BJU International, 2022, 130, 5-7.	2.5	10
11	The Importance of Training, Accreditation, and Guidelines for the Practice of Theranostics: The Australian Perspective. Journal of Nuclear Medicine, 2022, 63, 819-822.	5.0	9
12	A PET in a time of need: toward early PET-adapted therapy in DLBCL in first relapse. Leukemia and Lymphoma, 2022, 63, 1-4.	1.3	4
13	Utility of Biology-Guided Radiotherapy to De Novo Metastases Diagnosed During Staging of High-Risk Biopsy-Proven Prostate Cancer. Frontiers in Oncology, 2022, 12, 854589.	2.8	5
14	Quantitative assessment of ventilation-perfusion relationships with gallium-68 positron emission tomography/computed tomography imaging in lung cancer patients. Physics and Imaging in Radiation Oncology, 2022, 22, 8-12.	2.9	4
15	Management of Patients with Advanced Prostate Cancer: Report from the Advanced Prostate Cancer Consensus Conference 2021. European Urology, 2022, 82, 115-141.	1.9	51
16	Prostateâ€specific membrane antigen positron emission tomography/computed tomography funding grants free access to superior staging for Australian men with prostate cancer. BJU International, 2022, 130, 8-10.	2.5	6
17	Feasibility of biology-guided radiotherapy using PSMA-PET to boost to dominant intraprostatic tumour. Clinical and Translational Radiation Oncology, 2022, 35, 84-89.	1.7	3
18	Predictors and Real-World Use of Prostate-Specific Radioligand Therapy: PSMAÂand Beyond. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2022, , 366-382.	3.8	12

#	Article	IF	Citations
19	Circulating tumour cells (CTCs) and PSMA PET correlates in the phase I PRINCE trial of ¹⁷⁷Lu-PSMA-617 plus pembrolizumab for metastatic castration resistant prostate cancer (mCRPC).. Journal of Clinical Oncology, 2022, 40, 5027-5027.	1.6	1
20	PSMA PET tumor-to-salivary glands ratio (PSG score) to predict response to Lu-177 PSMA radioligand therapy: An international multicenter retrospective study.. Journal of Clinical Oncology, 2022, 40, 5043-5043.	1.6	5
21	TheraP: ¹⁷⁷Lu-PSMA-617 (LuPSMA) versus cabazitaxel in metastatic castration-resistant prostate cancer (mCRPC) progressing after docetaxelâ€"Overall survival after median follow-up of 3 years (ANZUP 1603).. Journal of Clinical Oncology, 2022, 40, 5000-5000.	1.6	44
22	PRINCE: Phase I trial of ¹⁷⁷Lu-PSMA-617 in combination with pembrolizumab in patients with metastatic castration-resistant prostate cancer (mCRPC).. Journal of Clinical Oncology, 2022, 40, 5017-5017.	1.6	15
23	Clinical Trial Protocol for LuTectomy: A Single-arm Study of the Dosimetry, Safety, and Potential Benefit of 177Lu-PSMA-617 Prior to Prostatectomy. European Urology Focus, 2021, 7, 234-237.	3.1	31
24	Is Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography Imaging Cost-effective in Prostate Cancer: An Analysis Informed by the proPSMA Trial. European Urology, 2021, 79, 413-418.	1.9	52
25	The role of ¹⁸Fâ€FDG PET/CT in retroperitoneal sarcomasâ€"A multicenter retrospective study. Journal of Surgical Oncology, 2021, 123, 1081-1087.	1.7	23
26	E-PSMA: the EANM standardized reporting guidelines v1.0 for PSMA-PET. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 1626-1638.	6.4	188
27	[177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial. Lancet, The, 2021, 397, 797-804.	13.7	552
28	Actinium-225 Prostate-specific Membrane Antigen Theranostics: Will Î± Beat Î²?. European Urology, 2021, 79, 351-352.	1.9	7
29	Positron Emission Tomography and Whole-body Magnetic Resonance Imaging for Metastasis-directed Therapy in Hormone-sensitive Oligometastatic Prostate Cancer After Primary Radical Treatment: A Systematic Review. European Urology Oncology, 2021, 4, 714-730.	5.4	16
30	Automated assessment of functional lung imaging with 68Ga-ventilation/perfusion PET/CT using iterative histogram analysis. EJNMMI Physics, 2021, 8, 23.	2.7	4
31	Intra-patient comparison of physiologic 68Ga-PSMA-11 and 18F-DCFPyL PET/CT uptake in ganglia in prostate cancer patients: a pictorial essay. Cancer Imaging, 2021, 21, 35.	2.8	2
32	UpFrontPSMA: a randomized phase 2 study of sequential ¹⁷⁷Luâ€PSMAâ€617 and docetaxel vs docetaxel in metastatic hormoneâ€naÃ¯ve prostate cancer (clinical trial protocol). BJU International, 2021, 128, 331-342.	2.5	33
33	Management of Persistently Elevated Prostate-specific Antigen After Radical Prostatectomy: A Systematic Review of the Literature. European Urology Oncology, 2021, 4, 150-169.	5.4	23
34	Prostate-specific Membrane Antigen PET in Prostate Cancer. Radiology, 2021, 299, 248-260.	7.3	38
35	Role of PSMA PET/CT imaging in the diagnosis, staging and restaging of prostate cancer. Future Oncology, 2021, 17, 2225-2241.	2.4	14
36	Perspectives on Cutting-Edge Clinical Trials. Journal of Nuclear Medicine, 2021, 62, 1027-1030.	5.0	0

#	Article	IF	Citations
37	Nodal metabolic tumour volume on baseline 18 Fâ€FDG PET/CT and overall survival in stage II and III NSCLC patients undergoing curativeâ€intent chemoradiotherapy/radiotherapy. Journal of Medical Imaging and Radiation Oncology, 2021, 65, 748-754.	1.8	1
38	ENZAâ€p trial protocol: a randomized phase II trial using prostateâ€specific membrane antigen as a therapeutic target and prognostic indicator in men with metastatic castrationâ€resistant prostate cancer treated with enzalutamide (ANZUP 1901). BJU International, 2021, 128, 642-651.	2.5	18
39	Radionuclide Therapy in Prostate Cancer: From Standalone to Combination PSMA Theranostics. Journal of Nuclear Medicine, 2021, 62, 1660-1668.	5.0	16
40	Bringing VISION to Nuclear Medicine: accelerating evidence and changing paradigms with theranostics. Journal of Nuclear Medicine, 2021, , jnumed.121.262890.	5.0	2
41	Targeted radioactive therapy for prostate cancer â€“ Authors' reply. Lancet, The, 2021, 398, 488.	13.7	0
42	Advanced prostate cancer experimental radioactive treatmentâ€”clinical trial decision making: patient experiences. BMJ Supportive and Palliative Care, 2021, , bmjspcare-2021-002994.	1.6	4
43	Molecular Imaging of Neuroendocrine Differentiation of Prostate Cancer: A Case Series. Clinical Genitourinary Cancer, 2021, 19, e200-e205.	1.9	16
44	Nomograms to predict outcomes after 177Lu-PSMA therapy in men with metastatic castration-resistant prostate cancer: an international, multicentre, retrospective study. Lancet Oncology, The, 2021, 22, 1115-1125.	10.7	120
45	The Additive Diagnostic Value of Prostate-specific Membrane Antigen Positron Emission Tomography Computed Tomography to Multiparametric Magnetic Resonance Imaging Triage in the Diagnosis of Prostate Cancer (PRIMARY): A Prospective Multicentre Study. European Urology, 2021, 80, 682-689.	1.9	181
46	The Global Reading Room: Nuclear Medicine Imaging of Suspected Paraganglioma. American Journal of Roentgenology, 2021, 217, 1008-1009.	2.2	1
47	The Australasian Radiopharmaceutical Trials Network: Clinical Trials, Evidence, and Opportunity. Journal of Nuclear Medicine, 2021, 62, 755-756.	5.0	4
48	Utility of <scp>⁶⁸Gaâ€DOTAâ€Exendin</scp>â€4 positron emission tomographyâ€“computed tomography imaging in distinguishing between insulinoma and nesidioblastosis in patients with confirmed endogenous hyperinsulinaemic hypoglycaemia. Internal Medicine Journal, 2021, 51, 1657-1664.	0.8	9
49	PSMA targeting in metastatic castration-resistant prostate cancer: where are we and where are we going?. Therapeutic Advances in Medical Oncology, 2021, 13, 175883592110538.	3.2	21
50	Gallium-68 Prostate-specific Membrane Antigen Positron Emission Tomography in Advanced Prostate Cancerâ€”Updated Diagnostic Utility, Sensitivity, Specificity, and Distribution of Prostate-specific Membrane Antigen-avid Lesions: A Systematic Review and Meta-analysis. European Urology, 2020, 77, 403-417.	1.9	614
51	Lutetium-177 prostate-specific membrane antigen (PSMA) theranostics: practical nuances and intricacies. Prostate Cancer and Prostatic Diseases, 2020, 23, 38-52.	3.9	50
52	Early Outcomes of Surgery for Carcinoid Heart Disease. Heart Lung and Circulation, 2020, 29, 742-747.	0.4	12
53	Detection and localisation of primary prostate cancer using ⁶⁸ gallium prostateâ€specific membrane antigen positron emission tomography/computed tomography compared with multiparametric magnetic resonance imaging and radical prostatectomy specimen pathology. BJU International, 2020, 126, 83-90.	2.5	69
54	Long-Term Follow-up and Outcomes of Retreatment in an Expanded 50-Patient Single-Center Phase II Prospective Trial of ¹⁷⁷Lu-PSMA-617 Theranostics in Metastatic Castration-Resistant Prostate Cancer. Journal of Nuclear Medicine, 2020, 61, 857-865.	5.0	191

#	Article	IF	Citations
55	Radiation Dosimetry in ¹⁷⁷Lu-PSMA-617 Therapy Using a Single Posttreatment SPECT/CT Scan: A Novel Methodology to Generate Time- and Tissue-Specific Dose Factors. Journal of Nuclear Medicine, 2020, 61, 1030-1036.	5.0	68
56	The evolving definition of bulky disease for lymphoma. Leukemia and Lymphoma, 2020, 61, 1525-1528.	1.3	2
57	Tumour Biology Characterisation by Imaging in Clinic. Medical Radiology, 2020, , 325-360.	0.1	0
58	Meeting report from the Prostate Cancer Foundation PSMA theranostics state of the science meeting. Prostate, 2020, 80, 1273-1296.	2.3	16
59	Monitoring DNA Damage and Repair in Peripheral Blood Mononuclear Cells of Lung Cancer Radiotherapy Patients. Cancers, 2020, 12, 2517.	3.7	8
60	Prostate-specific membrane antigen PET/computed tomography for staging prostate cancer. Current Opinion in Urology, 2020, 30, 628-634.	1.8	8
61	Technical Note: Rapid multiexponential curve fitting algorithm for voxelâ€based targeted radionuclide dosimetry. Medical Physics, 2020, 47, 4332-4339.	3.0	7
62	Efficacy and Safety of 177Lu-labeled Prostate-specific Membrane Antigen Radionuclide Treatment in Patients with Diffuse Bone Marrow Involvement: A Multicenter Retrospective Study. European Urology, 2020, 78, 148-154.	1.9	39
63	Prostateâ€specific membrane antigen theranostics in advanced prostate cancer: an evolving option. BJU International, 2020, 126, 525-535.	2.5	14
64	Abscopal Regressions of Lymphoma After Involved-Site Radiation Therapy Confirmed by Positron Emission Tomography. International Journal of Radiation Oncology Biology Physics, 2020, 108, 204-211.	0.8	10
65	Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study. Lancet, The, 2020, 395, 1208-1216.	13.7	1,108
66	Prognostic biomarkers in men with metastatic castration-resistant prostate cancer receiving [177Lu]-PSMA-617. European Journal of Nuclear Medicine and Molecular Imaging, 2020, 47, 2322-2327.	6.4	101
67	Teriparatide Promotes Bone Healing in Medication-Related Osteonecrosis of the Jaw: A Placebo-Controlled, Randomized Trial. Journal of Clinical Oncology, 2020, 38, 2971-2980.	1.6	61
68	Use of prostateâ€specific membrane antigen positronâ€emission tomography/CT in response assessment following upfront chemohormonal therapy in metastatic prostate cancer. BJU International, 2020, 126, 433-435.	2.5	13
69	Correlation between percutaneous biopsy and final histopathology for retroperitoneal sarcoma: a singleâ€centre study. ANZ Journal of Surgery, 2020, 90, 497-502.	0.7	14
70	Management of Patients with Advanced Prostate Cancer: Report of the Advanced Prostate Cancer Consensus Conference 2019. European Urology, 2020, 77, 508-547.	1.9	278
71	Protocol for the PRIMARY clinical trial, a prospective, multicentre, crossâ€sectional study of the additive diagnostic value of galliumâ€68 prostateâ€specific membrane antigen positronâ€emission tomography/computed tomography to multiparametric magnetic resonance imaging in the diagnostic setting for men being investigated for prostate cancer. BJU International, 2020, 125, 515-524.	2.5	51
72	Expanding the role of small-molecule PSMA ligands beyond PET staging ofÂprostate cancer. Nature Reviews Urology, 2020, 17, 107-118.	3.8	41

#	Article	IF	Citations
73	FDG PET/CT for tumoral and systemic immune response monitoring of advanced melanoma during first-line combination ipilimumab and nivolumab treatment. European Journal of Nuclear Medicine and Molecular Imaging, 2020, 47, 2776-2786.	6.4	42
74	ProPSMA: A Callout to the Nuclear Medicine Community to Change Practices with Prospective, High-Quality Data. Journal of Nuclear Medicine, 2020, 61, 676-677.	5.0	3
75	Mechanistic Insights for Optimizing PSMA Radioligand Therapy. Clinical Cancer Research, 2020, 26, 2774-2776.	7.0	11
76	Gallium-68 Ventilation/Perfusion PET-CT and CT Pulmonary Angiography for Pulmonary Embolism Diagnosis: An Interobserver Agreement Study. Frontiers in Medicine, 2020, 7, 599901.	2.6	0
77	Single-arm prospective interventional study assessing feasibility of using gallium-68 ventilation and perfusion PET/CT to avoid functional lung in patients with stage III non-small cell lung cancer. BMJ Open, 2020, 10, e042465.	1.9	15
78	TheraP: A randomised phase II trial of ¹⁷⁷Lu-PSMA-617 (LuPSMA) theranostic versus cabazitaxel in metastatic castration resistant prostate cancer (mCRPC) progressing after docetaxel: Initial results (ANZUP protocol 1603).. Journal of Clinical Oncology, 2020, 38, 5500-5500.	1.6	58
79	Correlation of positron emission tomography ventilation-perfusion matching with CT densitometry in severe emphysema. EJNMMI Research, 2020, 10, 86.	2.5	0
80	Prostate-Specific Membrane Antigen: The Target of the Decade, from Biochemical Recurrence to Widespread Adoption (perspective on â€œEvaluation of hybrid 68Ga-PSMA Ligand PET/CT in 248 Patients) Tj ETQq0 0 0 rgBT /Overlock Nuclear Medicine, 2020, 61, 246S-254S.	5.0	3
81	Editorial Comment. Journal of Urology, 2020, 203, 99-99.	0.4	0
82	Evaluating the PET Parameters SUVmax and TMTV in the Setting of Autologous Stem Cell Transplantation for DLBCL. Blood, 2020, 136, 38-38.	1.4	0
83	Role of PET/CT in multimodality imaging in differentiating cardiac sarcoidosis from arrhythmogenic right ventricular dysplasia. Journal of Nuclear Cardiology, 2019, 26, 1761-1765.	2.1	4
84	Tumour Heterogeneity and Resistance to Therapy in Prostate Cancer: A Fundamental Limitation of Prostate-specific Membrane Antigen Theranostics or a Key Strength?. European Urology, 2019, 76, 479-481.	1.9	7
85	18F-fluciclovine PET-CT and 68Ga-PSMA-11 PET-CT in patients with early biochemical recurrence after prostatectomy: a prospective, single-centre, single-arm, comparative imaging trial. Lancet Oncology, The, 2019, 20, 1286-1294.	10.7	338
86	Mitogen-Activated Protein Kinase Pathway Inhibition for Redifferentiation of Radioiodine Refractory Differentiated Thyroid Cancer: An Evolving Protocol. Thyroid, 2019, 29, 1634-1645.	4.5	69
87	What is the best PET target for early biochemical recurrence of prostate cancer?â€“Authorsâ€™ reply. Lancet Oncology, The, 2019, 20, e609-e610.	10.7	4
88	TheraP: a randomized phase 2 trial of ¹⁷⁷Luâ€<scp>PSMA</scp>â€617 theranostic treatment vs cabazitaxel in progressive metastatic castrationâ€resistant prostate cancer (Clinical Trial Protocol) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50	2.5	10
89	NaF PET/CT for response assessment of prostate cancer bone metastases treated with single fraction stereotactic ablative body radiotherapy. Radiation Oncology, 2019, 14, 164.	2.7	12
90	Poor Outcomes for Patients with Metastatic Castration-resistant Prostate Cancer with Low Prostate-specific Membrane Antigen (PSMA) Expression Deemed Ineligible for 177Lu-labelled PSMA Radioligand Therapy. European Urology Oncology, 2019, 2, 670-676.	5.4	134

#	Article	IF	Citations
91	Prostate-Specific Membrane Antigen Ligand Positron Emission Tomography in Men with Nonmetastatic Castration-Resistant Prostate Cancer. Clinical Cancer Research, 2019, 25, 7448-7454.	7.0	190
92	The Role of 68Ga-DOTA-Octreotate PET/CT in Follow-Up of SDH-Associated Pheochromocytoma and Paraganglioma. Journal of Clinical Endocrinology and Metabolism, 2019, 104, 5091-5099.	3.6	23
93	Guiding management of therapy in prostate cancer: time to switch from conventional imaging to PSMA PET?. Therapeutic Advances in Medical Oncology, 2019, 11, 175883591987682.	3.2	28
94	Going nuclear: it is time to embed the nuclear medicine physician in the prostate cancer multidisciplinary team. BJU International, 2019, 124, 551-553.	2.5	18
95	The role of 18F-FDG-PET/CT in evaluating retroperitoneal masses -Keeping your eye on the ball!. Cancer Imaging, 2019, 19, 28.	2.8	7
96	PET-detected pneumonitis following curative-intent chemoradiation in non-small cell lung cancer (NSCLC): recognizing patterns and assessing the impact on the predictive ability of FDG-PET/CT response assessment. European Journal of Nuclear Medicine and Molecular Imaging, 2019, 46, 1869-1877.	6.4	19
97	Characteristics and outcomes of therapy-related myeloid neoplasms after peptide receptor radionuclide/chemoradionuclide therapy (PRRT/PRCRT) for metastatic neuroendocrine neoplasia: a single-institution series. European Journal of Nuclear Medicine and Molecular Imaging, 2019, 46, 1902-1910.	6.4	37
98	Intra-individual comparison of 68Ga-PSMA-11 and 18F-DCFPyL normal-organ biodistribution. Cancer Imaging, 2019, 19, 23.	2.8	55
99	Independent and incremental value of ventilation/perfusion PET/CT and CT pulmonary angiography for pulmonary embolism diagnosis: results of the PECAN pilot study. European Journal of Nuclear Medicine and Molecular Imaging, 2019, 46, 1596-1604.	6.4	15
100	Strategies for Evaluation of Novel Imaging in Prostate Cancer: Putting the Horse Back Before the Cart. Journal of Clinical Oncology, 2019, 37, 765-769.	1.6	29
101	A Self-Fulfilling Prophecy: Comparing ¹⁷⁷Lu-PSMA Radioligand Therapy in Taxane-NaÃ¯ve Versus Posttaxane Metastasized Prostate Cancer Patients?. Journal of Nuclear Medicine, 2019, 60, 1494-1494.	5.0	1
102	Where to Next for Theranostics in Prostate Cancer?. European Urology Oncology, 2019, 2, 163-165.	5.4	9
103	A Novel Application of [18F]Fluorothymidine-PET ([18F]FLT-PET) in Clinical Practice to Quantify Regional Bone Marrow Function in a Patient With Treatment-Induced Cytopenias and to Guide â€œMarrow-Sparingâ€•Radiotherapy. Clinical Nuclear Medicine, 2019, 44, e624-e626.	1.3	6
104	The role of prostate-specific membrane antigen PET/computed tomography in primary staging of prostate cancer. Current Opinion in Urology, 2019, 29, 569-577.	1.8	17
105	The VAMPIRE challenge: A multiâ€institutional validation study of CT ventilation imaging. Medical Physics, 2019, 46, 1198-1217.	3.0	59
106	PET/CT Lung Ventilation and Perfusion Scanning using Galligas and Gallium-68-MAA. Seminars in Nuclear Medicine, 2019, 49, 71-81.	4.6	47
107	⁶⁴Cu-SARTATE PET Imaging of Patients with Neuroendocrine Tumors Demonstrates High Tumor Uptake and Retention, Potentially Allowing Prospective Dosimetry for Peptide Receptor Radionuclide Therapy. Journal of Nuclear Medicine, 2019, 60, 777-785.	5.0	98
108	Prostate-specific Membrane Antigen Across the Spectrum of Prostate Cancer: Detection, Surgery, and Theranostics. European Urology, 2019, 75, 927-928.	1.9	8

#	Article	IF	Citations
109	Highly favourable outcomes with peptide receptor radionuclide therapy (PRRT) for metastatic rectal neuroendocrine neoplasia (NEN). European Journal of Nuclear Medicine and Molecular Imaging, 2019, 46, 718-727.	6.4	17
110	PSMA PET applications in the prostate cancer journey: from diagnosis to theranostics. World Journal of Urology, 2019, 37, 1255-1261.	2.2	37
111	Voxelâ€wise correlation of positron emission tomography/computed tomography with multiparametric magnetic resonance imaging and histology of the prostate using a sophisticated registration framework. BJU International, 2019, 123, 1020-1030.	2.5	9
112	Dosimetry of ¹⁷⁷Lu-PSMA-617 in Metastatic Castration-Resistant Prostate Cancer: Correlations Between Pretherapeutic Imaging and Whole-Body Tumor Dosimetry with Treatment Outcomes. Journal of Nuclear Medicine, 2019, 60, 517-523.	5.0	285
113	Results of a 50 patient single-center phase II prospective trial of Lutetium-177 PSMA-617 theranostics in metastatic castrate-resistant prostate cancer.. Journal of Clinical Oncology, 2019, 37, 228-228.	1.6	7
114	The â€œProPSMA Studyâ€•clinical trial protocol: A prospective randomized multi-center study of the impact of Ga-68 PSMA PET/CT imaging for staging high-risk prostate cancer prior to curative-intent surgery or radiotherapy.. Journal of Clinical Oncology, 2019, 37, TPS138-TPS138.	1.6	1
115	TheraP: A randomized phase II trial of [¹⁷⁷Lu]-PSMA-617 theranostic versus cabazitaxel in progressive metastatic castration-resistant prostate cancer.. Journal of Clinical Oncology, 2019, 37, TPS332-TPS332.	1.6	6
116	Prospective head-to-head comparative phase 3 study between ¹⁸F-fluciclovine and ⁶⁸Ga-PSMA-11 PET/CT in patients with early biochemical recurrence of prostate cancer.. Journal of Clinical Oncology, 2019, 37, 5014-5014.	1.6	0
117	Impact of Post-Transplant Consolidative Radiotherapy in Patients with Relapsed or Refractory Classical Hodgkin Lymphoma and a PET-CT Based Predictive Model for Relapse. Blood, 2019, 134, 4044-4044.	1.4	1
118	Prostate-specific membrane antigen theranostics. Current Opinion in Urology, 2018, 28, 197-204.	1.8	39
119	Accuracy of Dose Calibrators for ⁶⁸Ga PET Imaging: Unexpected Findings in a Multicenter Clinical Pretrial Assessment. Journal of Nuclear Medicine, 2018, 59, 636-638.	5.0	31
120	Prostate-specific Membrane Antigen PET: Clinical Utility in Prostate Cancer, Normal Patterns, Pearls, and Pitfalls. Radiographics, 2018, 38, 200-217.	3.3	262
121	¹⁸F-FDGâ€“Avid Thyroid Incidentalomas: The Importance of Contextual Interpretation. Journal of Nuclear Medicine, 2018, 59, 749-755.	5.0	35
122	Cold Kit for Prostate-Specific Membrane Antigen (PSMA) PET Imaging: Phase 1 Study of 68Ga-Tris(Hydroxypyridinone)-PSMA PET/CT in Patients with Prostate Cancer. Journal of Nuclear Medicine, 2018, 59, 625-631.	5.0	62
123	Oligometastatic Renal Cell Carcinoma With Sarcomatoid Differentiation Demonstrating Variable Imaging Phenotypes on 68Ga-PSMA and 18F-FDG PET/CT: A Case Report and Review of the Literature. Clinical Genitourinary Cancer, 2018, 16, 1-5.	1.9	12
124	Peptide receptor radionuclide therapy (PRRT) in European Neuroendocrine Tumour Society (ENETS) grade 3 (G3) neuroendocrine neoplasia (NEN) - a single-institution retrospective analysis. European Journal of Nuclear Medicine and Molecular Imaging, 2018, 45, 262-277.	6.4	97
125	Using PSMA PET/CT to assess response in metastatic prostate cancer (mPC) patients (pts) receiving upfront chemohormonal therapy. Annals of Oncology, 2018, 29, ix70-ix71.	1.2	1
126	TROG 15.03 phase II clinical trial of Focal Ablative STereotactic Radiosurgery for Cancers of the Kidney - FASTRACK II. BMC Cancer, 2018, 18, 1030.	2.6	50

#	Article	IF	Citations
127	A pilot study of cardiopulmonary exercise testing and cardiac stress positron emission tomography before major nonâ€cardiac surgery. Anaesthesia, 2018, 73, 1524-1530.	3.8	1
128	Incidental Metastatic Melanoma Identified on 68Gaâ€“Prostate-Specific Membrane Antigen PET/CT for Metastatic Prostate Cancer. Clinical Nuclear Medicine, 2018, 43, 509-511.	1.3	8
129	Stereotactic Abative Body Radiotherapy (SABR) for Oligometastatic Prostate Cancer: A Prospective Clinical Trial. European Urology, 2018, 74, 455-462.	1.9	250
130	Guidelines on nuclear medicine imaging in neuroblastoma. European Journal of Nuclear Medicine and Molecular Imaging, 2018, 45, 2009-2024.	6.4	94
131	[177 Lu]-PSMA-617 radionuclide therapy in patients with metastatic castration-resistant prostate cancer â€“ Author's reply. Lancet Oncology, The, 2018, 19, e373.	10.7	10
132	Deep Learning Renal Segmentation for Fully Automated Radiation Dose Estimation in Unsealed Source Therapy. Frontiers in Oncology, 2018, 8, 215.	2.8	85
133	A First-in-Human Study of ⁶⁸Ga-Nanocolloid PET/CT Sentinel Lymph Node Imaging in Prostate Cancer Demonstrates Aberrant Lymphatic Drainage Pathways. Journal of Nuclear Medicine, 2018, 59, 1837-1842.	5.0	13
134	[177 Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study. Lancet Oncology, The, 2018, 19, 825-833.	10.7	823
135	Changes in biodistribution on 68Ga-DOTA-Octreotate PET/CT after long acting somatostatin analogue therapy in neuroendocrine tumour patients may result in pseudoprogression. Cancer Imaging, 2018, 18, 3.	2.8	45
136	A prospective randomized multicentre study of the impact of galliumâ€68 prostateâ€specific membrane antigen (PSMA) PET/CT imaging for staging highâ€risk prostate cancer prior to curativeâ€intent surgery or radiotherapy (proPSMA study): clinical trial protocol. BJU International, 2018, 122, 783-793.	2.5	96
137	Functional lung imaging in radiation therapy for lung cancer: A systematic review and meta-analysis. Radiotherapy and Oncology, 2018, 129, 196-208.	0.6	53
138	Advances in Urologic Imaging. Urologic Clinics of North America, 2018, 45, 503-524.	1.8	27
139	Lutetium-177 PSMA617 theranostics in metastatic castrate-resistant prostate cancer (mCRPC): Interim results of a phase II trial.. Journal of Clinical Oncology, 2018, 36, 5040-5040.	1.6	1
140	AGITG nabnec: A randomised phase II study of nab-paclitaxel in combination with carboplatin as first line treatment of gastrointestinal neuroendocrine carcinomas.. Journal of Clinical Oncology, 2018, 36, TPS548-TPS548.	1.6	0
141	The poor outcome of patients with mCRPC whom were deemed ineligible for PSMA theranostics based on molecular imaging characteristics.. Journal of Clinical Oncology, 2018, 36, e17002-e17002.	1.6	1
142	Bringing clarity or confusion? The role of prostateâ€specific membrane antigen positronâ€emission/computed tomography for primary staging in prostate cancer. BJU International, 2017, 119, 194-195.	2.5	19
143	Utility of ⁶⁸Ga prostate specific membrane antigen â€“ positron emission tomography in diagnosis and response assessment of recurrent renal cell carcinoma. Journal of Medical Imaging and Radiation Oncology, 2017, 61, 372-378.	1.8	83
144	Gallium-68 Prostate-Specific Membrane Antigen PET Imaging. PET Clinics, 2017, 12, 219-234.	3.0	29

#	Article	IF	Citations
145	Early treatment intensification with R-ICE and 90Y-ibritumomab tiuxetan (Zevalin)-BEAM stem cell transplantation in patients with high-risk diffuse large B-cell lymphoma patients and positive interim PET after 4 cycles of R-CHOP-14. Haematologica, 2017, 102, 356-363.	3.5	53
146	Early warning signs: FDG-PET to diagnose bleomycin toxicity. Leukemia and Lymphoma, 2017, 58, 1016-1018.	1.3	3
147	FDG PET in follicular lymphoma: more than a staging test?. Leukemia and Lymphoma, 2017, 58, 1521-1523.	1.3	1
148	Development of standardized image interpretation for 68Ga-PSMA PET/CT to detect prostate cancer recurrent lesions. European Journal of Nuclear Medicine and Molecular Imaging, 2017, 44, 1622-1635.	6.4	91
149	Detection of Synchronous Primary Malignancies with ⁶⁸Ga-Labeled Prostate-Specific Membrane Antigen PET/CT in Patients with Prostate Cancer: Frequency in 764 Patients. Journal of Nuclear Medicine, 2017, 58, 1938-1942.	5.0	38
150	Efficacy of Peptide Receptor Radionuclide Therapy for Functional Metastatic Paraganglioma and Pheochromocytoma. Journal of Clinical Endocrinology and Metabolism, 2017, 102, 3278-3287.	3.6	125
151	Glut-1 expression in small cervical biopsies is prognostic in cervical cancers treated with chemoradiation. Clinical and Translational Radiation Oncology, 2017, 2, 53-58.	1.7	8
152	68 Ga-prostate-specific membrane antigen-positron emission tomography/computed tomography in advanced prostate cancer: Current state and future trends. Prostate International, 2017, 5, 125-129.	2.3	36
153	Prostateâ€specific membrane antigen from diagnostic to therapeutic target: radionuclide therapy comes of age in prostate cancer. BJU International, 2017, 120, 310-312.	2.5	5
154	The Advantages and Challenges of Using FDG PET/CT for Response Assessment in Melanoma in the Era of Targeted Agents and Immunotherapy. European Journal of Nuclear Medicine and Molecular Imaging, 2017, 44, 67-77.	6.4	112
155	Principles and Application of Molecular Imaging for Personalized Medicine and Guiding Interventions in Neuroendocrine Tumors. , 2017, , 219-238.		2
156	Role of PET/CT in Melanoma. , 2017, , 37-51.		0
157	PET/CT in Melanoma (Additional Teaching Cases). , 2017, , 53-63.		0
158	Prostate-Specific Membrane Antigen Ligands for Imaging and Therapy. Journal of Nuclear Medicine, 2017, 58, 67S-76S.	5.0	163
159	Accuracy in the Eye of the Beholder: Can We Improve Agreement in Prostate Cancer Diagnostics with PSMA PET/CT?. Journal of Nuclear Medicine, 2017, 58, 1615-1616.	5.0	0
160	EORTC PET response criteria are more influenced by reconstruction inconsistencies than PERCIST but both benefit from the EARL harmonization program. EJNMMI Physics, 2017, 4, 17.	2.7	14
161	Reply to Fabio Zattoni, Filiberto Zattoni, and Laura Evangelista's Letter to the Editor re: Marlon Perera, Nathan Papa, Daniel Christidis, et al. Sensitivity, Specificity, and Predictors of Positive 68 Gaâ€"Prostate-specific Membrane Antigen Positron Emission Tomography in Advanced Prostate Cancer: A Systematic Review and Meta-analysis. Eur Urol 2016;70:926â€"37. European Urology, 2017, 71, e66-e67.	1.9	2
162	High clinical and morphologic response using 90Y-DOTA-octreotate sequenced with 177Lu-DOTA-octreotate induction peptide receptor chemoradionuclide therapy (PRCRT) for bulky neuroendocrine tumours. European Journal of Nuclear Medicine and Molecular Imaging, 2017, 44, 476-489.	6.4	42

#	Article	IF	Citations
163	PSMA-PET for Lymph Node Detection in Recurrent Prostate Cancer: How do we use the Magic Bullet?. Theranostics, 2017, 7, 2046-2047.	10.0	12
164	Automatic delineation of functional lung volumes with 68Ga-ventilation/perfusion PET/CT. EJNMMI Research, 2017, 7, 82.	2.5	19
165	68Ga PSMA-11 PET with CT urography protocol in the initial staging and biochemical relapse of prostate cancer. Cancer Imaging, 2017, 17, 31.	2.8	20
166	Reduced ventilation-perfusion (V/Q) mismatch following endobronchial valve insertion demonstrated by Gallium-68 V/Q photon emission tomography/computed tomography. Respirology Case Reports, 2017, 5, e00253.	0.6	8
167	Patterns of failure on Ga PSMA (GaPSMA) and F18 FDG (FDG) PET CT in a prospective phase 2 trial of 177Lu DKFZ PSMA 617 (LuPSMA) in men with castrate resistant metastatic prostate cancer (mCRPC).. Journal of Clinical Oncology, 2017, 35, 2562-2562.	1.6	0
168	Outcomes of peptide receptor radionuclide therapy (PRRT) in metastatic grade 3 neuroendocrine tumors (NETs).. Journal of Clinical Oncology, 2017, 35, e15694-e15694.	1.6	1
169	Initial Experience With Gallium-68 DOTA-Octreotate PET/CT and Peptide Receptor Radionuclide Therapy for Pediatric Patients With Refractory Metastatic Neuroblastoma. Journal of Pediatric Hematology/Oncology, 2016, 38, 87-96.	0.6	102
170	68Ga-DOTATATE and 18F-FDG PET/CT in Paraganglioma and Pheochromocytoma: utility, patterns and heterogeneity. Cancer Imaging, 2016, 16, 22.	2.8	135
171	Impact of stereotactic radiotherapy on kidney function in primary renal cell carcinoma: Establishing a doseâ€“response relationship. Radiotherapy and Oncology, 2016, 118, 540-546.	0.6	60
172	V4-07 EARLY EXPERIENCE OF ROBOTIC SALVAGE PELVIC LYMPH NODE DISSECTION IN THE GA-68 PSMA PET SCANNING ERA. Journal of Urology, 2016, 195, .	0.4	0
173	Short and long-term prognostic implications of a low embolic burden in oncology patients diagnosed with symptomatic pulmonary embolism. Annals of Hematology, 2016, 95, 651-652.	1.8	2
174	Gallium-68 EDTA PET/CT for Renal Imaging. Seminars in Nuclear Medicine, 2016, 46, 448-461.	4.6	29
175	Neuraxial Anesthesia Reduces Lymphatic Flow. Anesthesia and Analgesia, 2016, 123, 1325-1327.	2.2	8
176	Intense focal pituitary FDG uptake due to intravascular large Bâ€cell lymphoma in pyrexia of unknown origin. American Journal of Hematology, 2016, 91, 1167-1168.	4.1	2
177	How We Read Oncologic FDG PET/CT. Cancer Imaging, 2016, 16, 35.	2.8	81
178	Prognostic biomarkers in locally advanced cervical cancer (Cx Ca) treated with chemoradiation (CRT). Annals of Oncology, 2016, 27, vi35.	1.2	0
179	Gallium-68 perfusion positron emission tomography/computed tomography to assess pulmonary function in lung cancer patients undergoing surgery. Cancer Imaging, 2016, 16, 24.	2.8	19
180	Rapidly changing landscape of PET/CT imaging in prostate cancer. Current Opinion in Urology, 2016, 26, 493-500.	1.8	7

#	Article	IF	Citations
181	Does PET SUV Harmonization Affect PERCIST Response Classification?. Journal of Nuclear Medicine, 2016, 57, 1699-1706.	5.0	31
182	Sensitivity, Specificity, and Predictors of Positive 68 Gaâ€“Prostate-specific Membrane Antigen Positron Emission Tomography in Advanced Prostate Cancer: A Systematic Review and Meta-analysis. European Urology, 2016, 70, 926-937.	1.9	819
183	Ga-68 MAA Perfusion 4D-PET/CT Scanning Allows for Functional Lung Avoidance Using Conformal Radiation Therapy Planning. Technology in Cancer Research and Treatment, 2016, 15, 114-121.	1.9	33
184	â€˜Hot spotâ€™ cardiac ischemia imaging with fluorodeoxyglucose positron emission tomography. Journal of Nuclear Cardiology, 2016, 23, 1514-1517.	2.1	2
185	Estimating lung ventilation directly from 4D CT Hounsfield unit values. Medical Physics, 2015, 43, 33-43.	3.0	42
186	Somatostatin Receptor Imaging with⁶⁸Ga DOTATATE PET/CT: Clinical Utility, Normal Patterns, Pearls, and Pitfalls in Interpretation. Radiographics, 2015, 35, 500-516.	3.3	435
187	⁶⁸Ga-EDTA PET/CT Imaging and Plasma Clearance for Glomerular Filtration Rate Quantification: Comparison to Conventional ⁵¹Cr-EDTA. Journal of Nuclear Medicine, 2015, 56, 405-409.	5.0	32
188	Favourable outcomes of 177Lu-octreotate peptide receptor chemoradionuclide therapy in patients with FDG-avid neuroendocrine tumours. European Journal of Nuclear Medicine and Molecular Imaging, 2015, 42, 176-185.	6.4	91
189	Distribution Atlas of Proliferating Bone Marrow in Non-Small Cell Lung Cancer Patients Measured by FLT-PET/CT Imaging, With Potential Applicability in Radiation Therapy Planning. International Journal of Radiation Oncology Biology Physics, 2015, 92, 1035-1043.	0.8	31
190	Pulmonary Scintigraphy for the Diagnosis of Acute Pulmonary Embolism: A Survey of Current Practices in Australia, Canada, and France. Journal of Nuclear Medicine, 2015, 56, 1212-1217.	5.0	36
191	High-resolution pulmonary ventilation and perfusion PET/CT allows for functionally adapted intensity modulated radiotherapy in lung cancer. Radiotherapy and Oncology, 2015, 115, 157-162.	0.6	83
192	Moving Beyond â€œLumpologyâ€• PET/CT Imaging of Pheochromocytoma and Paraganglioma. Clinical Cancer Research, 2015, 21, 3815-3817.	7.0	24
193	Modifying the Poor Prognosis Associated with ¹⁸F-FDGâ€“Avid NET with Peptide Receptor Chemo-Radionuclide Therapy (PRCRT). Journal of Nuclear Medicine, 2015, 56, 968-969.	5.0	17
194	Harmonizing FDG PET quantification while maintaining optimal lesion detection: prospective multicentre validation in 517 oncology patients. European Journal of Nuclear Medicine and Molecular Imaging, 2015, 42, 2072-2082.	6.4	81
195	Re: Palliative bypass for small bowel carcinoid with mesenteric mass and vascular encasement. ANZ Journal of Surgery, 2015, 85, 197-197.	0.7	1
196	Current status of FDG-PET/CT in staging of adult lymphoma. Clinical and Translational Imaging, 2015, 3, 253-269.	2.1	4
197	Role of Fluorodeoxyglucose PET/Computed Tomography in Targeted Radionuclide Therapy for Endocrine Malignancies. PET Clinics, 2015, 10, 461-476.	3.0	21
198	Accuracy and Utility of Deformable Image Registration in 68Ga 4D PET/CT Assessment of Pulmonary Perfusion Changes During and After Lung Radiation Therapy. International Journal of Radiation Oncology Biology Physics, 2015, 93, 196-204.	0.8	21

#	Article	IF	Citations
199	Correlation of ⁶⁸Ga Ventilationâ€“Perfusion PET/CT with Pulmonary Function Test Indices for Assessing Lung Function. Journal of Nuclear Medicine, 2015, 56, 1718-1723.	5.0	29
200	Ventilation/Perfusion Positron Emission Tomographyâ€”Based Assessment of Radiation Injury to Lung. International Journal of Radiation Oncology Biology Physics, 2015, 93, 408-417.	0.8	41
201	The utility and limitations of18F-fluorodeoxyglucose positron emission tomography with computed tomography in patients with primary mediastinal B-cell lymphoma: single institution experience and literature review. Leukemia and Lymphoma, 2015, 56, 49-56.	1.3	16
202	Prolonged life-threatening hypoglycaemia following dose escalation of octreotide LAR in a patient with malignant polysecreting pancreatic neuroendocrine tumour. Endocrinology, Diabetes and Metabolism Case Reports, 2015, 2015, 140097.	0.5	9
203	Unintended consequences: might major surgery accelerate cancer?. BMJ, The, 2014, 348, g247-g247.	6.0	1
204	Short communication: timeline of radiation-induced kidney function loss after stereotactic ablative body radiotherapy of renal cell carcinoma as evaluated by serial 99mTc-DMSA SPECT/CT. Radiation Oncology, 2014, 9, 253.	2.7	26
205	A prospective observational study of Gallium-68 ventilation and perfusion PET/CT during and after radiotherapy in patients with non-small cell lung cancer. BMC Cancer, 2014, 14, 740.	2.6	26
206	The predictive role of interim positron emission tomography for Hodgkin lymphoma treatment outcome is confirmed using the interpretation criteria of the Deauville five-point scale. Haematologica, 2014, 99, 1107-1113.	3.5	225
207	Protracted hypocalcaemia following a single dose of denosumab in humoral hypercalcaemia of malignancy due to PTHrP-secreting neuroendocrine tumour. Clinical Endocrinology, 2014, 81, 940-942.	2.4	12
208	PET Screening for Metastatic Colorectal Adenocarcinoma. JAMA - Journal of the American Medical Association, 2014, 312, 1255.	7.4	0
209	Peptide receptor radionuclide therapy for neuroendocrine tumours: standardized and randomized, or personalized?. European Journal of Nuclear Medicine and Molecular Imaging, 2014, 41, 211-213.	6.4	27
210	High-resolution imaging of pulmonary ventilation and perfusion with 68Ga-VQ respiratory gated (4-D) PET/CT. European Journal of Nuclear Medicine and Molecular Imaging, 2014, 41, 343-349.	6.4	43
211	Enhanced White Adipose Tissue Metabolism in Iatrogenic Cushing's Syndrome With FDG PET/CT. Journal of Clinical Endocrinology and Metabolism, 2014, 99, 3041-3042.	3.6	11
212	Assessment of predictors of response and long-term survival of patients with neuroendocrine tumour treated with peptide receptor chemoradionuclide therapy (PRCRT). European Journal of Nuclear Medicine and Molecular Imaging, 2014, 41, 1831-1844.	6.4	79
213	Limited clinical benefit for surveillance PET-CT scanning in patients with histologically transformed lymphoma in complete metabolic remission following primary therapy. Annals of Hematology, 2014, 93, 1193-1200.	1.8	18
214	Fluorodeoxyglucose positron emission tomography/computed tomography: a "one stop shop" for diagnosing polymyalgia rheumatica. BMJ, The, 2014, 348, f7705-f7705.	6.0	2
215	Segmental Hyperperfusion in Lobar Pneumonia Visualized with Respiratory-gated Four-Dimensional Pulmonary Perfusion Positron Emission Tomographyâ€“Computed Tomography. American Journal of Respiratory and Critical Care Medicine, 2014, 189, 104-105.	5.6	4
216	Rapid blood clearance and lack of long-term renal toxicity of 177Lu-DOTATATE enables shortening of renoprotective amino acid infusion. European Journal of Nuclear Medicine and Molecular Imaging, 2013, 40, 1853-1860.	6.4	32

#	Article	IF	Citations
217	High FDG activity in focal fat necrosis: a pitfall in interpretation of posttreatment PET/CT in patients with non-Hodgkin lymphoma. European Journal of Nuclear Medicine and Molecular Imaging, 2013, 40, 1330-1336.	6.4	17
218	Radiotherapy of abdomen with precise renal assessment with SPECT/CT imaging (RAPRASI): design and methodology of a prospective trial to improve the understanding of kidney radiation dose response. BMC Cancer, 2013, 13, 381.	2.6	12
219	International Validation Study for Interim PET in ABVD-Treated, Advanced-Stage Hodgkin Lymphoma: Interpretation Criteria and Concordance Rate Among Reviewers. Journal of Nuclear Medicine, 2013, 54, 683-690.	5.0	267
220	Improving Diagnosis of Tumor-Induced Osteomalacia With Gallium-68 DOTATATE PET/CT. Journal of Clinical Endocrinology and Metabolism, 2013, 98, 687-694.	3.6	100
221	Evaluating the place of 18-fluoro-2-deoxy-d-glucose positron emission tomography scanning in primary staging and beyond in patients with follicular lymphoma. Leukemia and Lymphoma, 2013, 54, 2093-2095.	1.3	3
222	Not-So-Random Errors: Randomized Controlled Trials Are Not the Only Evidence of the Value of PETâ€"Rebuttal. Journal of Nuclear Medicine, 2013, 54, 492-492.	5.0	4
223	Validating and improving CT ventilation imaging by correlating with ventilation 4D-PET/CT using ⁶⁸ Ga-labeled nanoparticles. Medical Physics, 2013, 41, 011910.	3.0	79
224	Let's Get SEERious: More Accurate Staging With Consequent High Management Impact Is Not Just Stage Migration. Journal of Clinical Oncology, 2013, 31, 819-819.	1.6	4
225	Limited role for surveillance PETâ€"CT scanning in patients with diffuse large B-cell lymphoma in complete metabolic remission following primary therapy. British Journal of Cancer, 2013, 109, 312-317.	6.4	64
226	Evaluation of a new visual uptake scoring scale for 18F-fluorothymidine positron emission tomography in the diagnosis of pulmonary lesions. Nuclear Medicine Communications, 2013, 34, 521-526.	1.1	5
227	An automated voxelized dosimetry tool for radionuclide therapy based on serial quantitative SPECT/CT imaging. Medical Physics, 2013, 40, 112503.	3.0	66
228	Thyroid nodules: time to stop over-reporting normal findings and update consensus guidelines. BMJ, The, 2013, 347, f5742-f5742.	6.0	5
229	TU-A-WAB-08: Strong Evidence for Physiologic Correlation of 4D-CT Ventilation Imaging with Respiratory-Correlated Gallium 68 PET/CT in Humans. Medical Physics, 2013, 40, 424-424.	3.0	3
230	Lack Of Benefit From Surveillance PET-CT In Transformed Indolent Lymphoma (TrIL) In Complete Metabolic Remission (CMR) Following Therapy. Blood, 2013, 122, 1796-1796.	1.4	0
231	Special delivery: getting radiation to the target in diffuse large B-cell lymphoma. Leukemia and Lymphoma, 2012, 53, 751-753.	1.3	0
232	Not-So-Random Errors: Randomized Controlled Trials Are Not the Only Evidence of the Value of PET. Journal of Nuclear Medicine, 2012, 53, 1820-1822.	5.0	5
233	Fluorodeoxyglucose positron emission tomography/computed tomography for evaluation of bone marrow involvement in lymphoma: when is it superior to biopsy?. Leukemia and Lymphoma, 2012, 53, 349-351.	1.3	5
234	Is there still a role for SPECTâ€"CT in oncology in the PETâ€"CT era?. Nature Reviews Clinical Oncology, 2012, 9, 712-720.	27.6	135

#	Article	IF	Citations
235	The potential for induction peptide receptor chemoradionuclide therapy to render inoperable pancreatic and duodenal neuroendocrine tumours resectable. European Journal of Surgical Oncology, 2012, 38, 64-71.	1.0	65
236	High management impact of Gaâ€68 DOTATATE (GaTate) PET/CT for imaging neuroendocrine and other somatostatin expressing tumours. Journal of Medical Imaging and Radiation Oncology, 2012, 56, 40-47.	1.8	217
237	The tumour sink effect on the biodistribution of 68Ga-DOTA-octreotate: implications for peptide receptor radionuclide therapy. European Journal of Nuclear Medicine and Molecular Imaging, 2012, 39, 50-56.	6.4	119
238	Breast Cancer: Role of Planar, SPECT and PET in Imaging Bone Metastases. , 2012, , 661-689.		0
239	Changing paradigms with molecular imaging of neuroendocrine tumors. Discovery Medicine, 2012, 14, 71-81.	0.5	59
240	⁶⁸Ga PET/CT Ventilationâ€"Perfusion Imaging for Pulmonary Embolism: A Pilot Study with Comparison to Conventional Scintigraphy. Journal of Nuclear Medicine, 2011, 52, 1513-1519.	5.0	87
241	Imaging in follicular NHL. Best Practice and Research in Clinical Haematology, 2011, 24, 165-177.	1.7	15
242	Quantitative 177 Lu SPECT (QSPECT) imaging using a commercially available SPECT/CT system. Cancer Imaging, 2011, 11, 56-66.	2.8	111
243	White fat, factitious hyperglycemia, and the role of FDG PET to enhance understanding of adipocyte metabolism. EJNMMI Research, 2011, 1, 2.	2.5	11
244	Breast lymphatic drainage via the pulmonary lymphatic system. European Journal of Nuclear Medicine and Molecular Imaging, 2010, 37, 2203-2203.	6.4	4
245	Restaging: Should We PERCIST Without Pattern Recognition?. Journal of Nuclear Medicine, 2010, 51, 1830-1832.	5.0	7
246	The role of chemotherapeutic drugs in the evaluation of breast tumour response to chemotherapy using serial FDG-PET. Breast Cancer Research, 2010, 12, R37.	5.0	31
247	Using positron emission tomography to assess tumor proliferation in non-Hodgkin lymphoma. Leukemia and Lymphoma, 2010, 51, 183-185.	1.3	2
248	Observer Variation in Interpreting ¹⁸F-FDG PET/CT Findings for Lymphoma Staging. Journal of Nuclear Medicine, 2009, 50, 1594-1597.	5.0	40
249	Observer variation in FDG PET-CT for staging of non-small-cell lung carcinoma. European Journal of Nuclear Medicine and Molecular Imaging, 2009, 36, 194-199.	6.4	12
250	Routine positron emission tomography and positron emission tomography/computed tomography in melanoma staging with positive sentinel node biopsy is of limited benefit. Melanoma Research, 2008, 18, 56-60.	1.2	39
251	Assessing response to chemotherapy in metastatic melanoma with FDG PET: Early experience. Nuclear Medicine Communications, 2007, 28, 902-906.	1.1	29
252	False-Negative Myocardial Perfusion Scintigraphy Possibly as a Result of Administration of Low-Molecular-Weight Heparin. Clinical Nuclear Medicine, 2007, 32, 70-72.	1.3	2

#	Article	IF	Citations
253	How do we best balance optimal timing of FDG PETâ€“CT imaging?. Nuclear Medicine Communications, 2007, 28, 885-887.	1.1	3
254	Meningeal recurrence of intravascular large B-cell lymphoma: early diagnosis with PET-CT. British Journal of Haematology, 2007, 137, 386-386.	2.5	12
255	Efficacy of milk versus water to reduce interfering infra-cardiac activity in 99mTc-sestamibi myocardial perfusion scintigraphy. Nuclear Medicine Communications, 2006, 27, 837-842.	1.1	22
256	Development and Validation of Nomograms to Predict Outcome Following LuPSMA Radionuclide Treatment for Metastatic Castration-Resistant Prostate Cancer: A Multicenter International Study. SSRN Electronic Journal, 0, , .	0.4	0